192 related articles for article (PubMed ID: 22431549)
1. Association of JAK2 mutation status and cytogenetic abnormalities at diagnosis in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Zamora L; Xandri M; Garcia O; Marcé S; Xicoy B; Granada I; Navarro JT; Millá F
Am J Clin Pathol; 2012 Apr; 137(4):677-8. PubMed ID: 22431549
[No Abstract] [Full Text] [Related]
2. Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Dunlap J; Kelemen K; Leeborg N; Braziel R; Olson S; Press R; Huang J; Gatter K; Loriaux M; Fan G
Am J Clin Pathol; 2011 May; 135(5):709-19. PubMed ID: 21502425
[TBL] [Abstract][Full Text] [Related]
3. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
4. Concurrent
Ye MT; Wang Y; Wang SA; Pemmaraju N; Daver N; Verstovsek S; Zhang Y; Zuo Z; Medeiros LJ; You MJ
Leuk Lymphoma; 2020 Apr; 61(4):963-966. PubMed ID: 31750750
[No Abstract] [Full Text] [Related]
5. Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.
Salmoiraghi S; Montalvo ML; D'Agostini E; Amicarelli G; Minnucci G; Spinelli O; Rambaldi A
Expert Rev Hematol; 2013 Aug; 6(4):429-39. PubMed ID: 23991929
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
[TBL] [Abstract][Full Text] [Related]
7. [JAK2 mutation in myeloproliferative disorders].
Inokuchi K
Rinsho Ketsueki; 2006 Aug; 47(8):693-700. PubMed ID: 16986707
[No Abstract] [Full Text] [Related]
8. [A case report of myelodysplastic/myeloproliferative disease unclassifiable with karyotype aberration of trisomy 8 and JAK2 mutation].
Liu K; Ying CX; Chen XD; Zhou XY; Guo KY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1139-43. PubMed ID: 23114135
[TBL] [Abstract][Full Text] [Related]
9. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera.
Inano T; Araki M; Morishita S; Imai M; Yasuda H; Nitta H; Ito M; Edahiro Y; Ochiai T; Misawa K; Fukuda Y; Ohsaka A; Komatsu N
Br J Haematol; 2019 Oct; 187(1):e27-e31. PubMed ID: 31418453
[No Abstract] [Full Text] [Related]
10. Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Rumi E; Cazzola M
Haematologica; 2014 Nov; 99(11):1650-2. PubMed ID: 25420280
[No Abstract] [Full Text] [Related]
11. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P
Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884
[TBL] [Abstract][Full Text] [Related]
13. [Research progress on gene mutation of jak2].
Liu L; Li W; Liu N; Pang L; Feng SX; Zhao LL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1629-32. PubMed ID: 20030962
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis with co-mutated JAK2 and SF3B1.
Reinig EF; He R
Blood; 2017 Feb; 129(5):656. PubMed ID: 28153838
[No Abstract] [Full Text] [Related]
15. Cardiac JAK2 mutation V617F in a patient with cardiomyopathy and myeloproliferative disease.
Gattenlohner S; Ertl G; Einsele H; Kircher S; Muller-Hermelink HK; Marx A
Ann Intern Med; 2008 Jul; 149(1):69-71. PubMed ID: 18591647
[No Abstract] [Full Text] [Related]
16. Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F.
Gibson SE; Schade AE; Szpurka H; Bak B; Maciejewski JP; Hsi ED
Hum Pathol; 2008 Jul; 39(7):1111-4. PubMed ID: 18479730
[TBL] [Abstract][Full Text] [Related]
17. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
Sun T; Zhang L
Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL1-positive and JAK2 V617F-positive clones in 23 patients with both aberrations reveal biologic and clinical importance.
Martin-Cabrera P; Haferlach C; Kern W; Schnittger S; Haferlach T
Br J Haematol; 2017 Jan; 176(1):135-139. PubMed ID: 26847954
[No Abstract] [Full Text] [Related]
19. Association of JAK2-V617F Mutations Detected by Solid Tumor Sequencing With Coexistent Myeloproliferative Neoplasms.
Riedlinger G; Hadigol M; Khiabanian H; Ganesan S
JAMA Oncol; 2019 Feb; 5(2):265-267. PubMed ID: 30605212
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome.
Colaizzo D; Amitrano L; Tiscia GL; Iannaccone L; Gallone A; Grandone E; Guardascione MA; Margaglione M
Blood Coagul Fibrinolysis; 2008 Jul; 19(5):459-62. PubMed ID: 18600100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]